Sisu Pharma
Sisu Pharma exploits cellular stress by directly targeting HSF1, the Master Regulator of the heat shock response. Our HSF1 targeting platform (HI-LiTe) is being developed to deliver selective HSF1 degraders for oncology and therapies for use in neurodegenerative conditions and infection, providing a unique approach to treating these devastating diseases.
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
2
1 to 10 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
41
organic / mo
Sign up free to see all 2 verified contacts at Sisu Pharma
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
Showing 1 of 2 verified contacts
Top roles at Sisu Pharma
2 distinct titles indexed · top 2 shown.
- 1chief scientific officer
- 1cofounder and ceo
Sign up to unlock all 2 contacts at Sisu Pharma
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Sisu Pharma
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.